|
|
 |
|
Viewing report
|
|
|
|
Drug Delivery: Active Transdermal Delivery Systems
Greystone Associates, Oct 2007, Pages: 125
Compliance concerns have driven and continue to drive investment in new drug delivery technologies. The transdermal patch and implantable drug reservoirs are two prominent examples of this impact. As work with passive transdermal systems has progressed, so too has the realization of the true extent of the barrier to drug delivery presented by the stratum corneum, the skins outer layer of dead, hydrophobic, keratinized cells. Passive permeation of compounds through the skin became a major problem and very soon restricted the choice of compounds that were eligible for delivery in that manner.
To expand the limits of transdermal drug delivery, developers are employing microporation techniques and energy sources such as ultrasound, heat and electrical current to affect active transport through the skin. These techniques can increase the upper molecular size limit dramatically, opening up a host of opportunities for transdermal delivery. To take full advantage of these evolving dynamics, active transdermal delivery participants must deal with a number of economic and market forces influencing the way drug companies develop and commercialize their products. Success will favor those sector participants willing to incorporate patient-centric design features and drug-device combination engineering paradigms into their product development programs.
The advantages of transdermal drug delivery for improving patient compliance, particularly for the treatment of chronic conditions, are well known. But growth of transdermal delivery has been restricted by the need to limit candidate drugs to molecules small enough to effectively pass through the stratum corneum, a limitation that excludes passive transdermal patches as a viableoption for the growing number of protein and peptide therapeutic compounds that will represent an increasing share of future NCEs.
To expand the limits of transdermal drug delivery, developers are employing energy sources such as ultrasound, heat and electrical current to affect active transport through the skin. Another approach is the modification or removal of surface skin layers, a group of technologies collectively referred to as microporation, which can be used alone or in conjunction with energyenabled devices to expand the size and type of drug molecules capable of transdermal delivery. These techniques can increase the upper molecular size limit dramatically, opening up a host of opportunities for transdermal delivery.
Market Data
The study presents qualitative and quantitative data and information on key market measures and benchmarks:
- Market Size by Segment
- Company Market Share
- Demand Drivers
- Technology Market Share
- Industry Structure
- Economic Factors
- System Design Criteria
- Development Status
- Emerging Markets and Therapies
- Strategic Alliances
- Market Projections
- Proprietary Technology
- Technology Factors
- Market Factors
- Regulatory Factors
Methodology
Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations.
Primary data is evaluated and normalized against secondary sources including trade journal articles, technical literature, industry publications, company data sheets and published information, and statistical data from government agencies and trade associations.
Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques.
Feature Summary
- Analyzes and evaluates active transdermal products and assesses the market potential for existing and probable future products
- Analyzes product designs, technologies and market development issues
- Provides detailed descriptions of transdermal delivery market segments, market demographics, and business strategies
- Charts product sales data, market share, and forecasts to 2010
- Profiles active transdermal delivery companies, their product development activities, business strategies, and corporate alliances and affiliations
- Assesses the importance of pharma-device alliances and design partnerships on future active transdermal products
- Evaluates the impact of economic, technology, and regulatory factors on transdermal drug delivery markets
Forecasts and projections cover the period from 2007 to 2010.
Customers who bought this item also bought
Active Transdermal Delivery
Transdermal Drug Delivery: Patches, Gels, Active Systems, Therapeutics, Markets & Forecasts
Transdermal Drug Delivery - Technologies, Markets, and Companies
Transdermal Skin Patches: Markets and Opportunities 2009
The Top 40 Transdermal Drug Delivery Technology Companies Worldwide
Transdermal Pain Management: Markets, Demand Factors, Forecasts, and Opportunities
Transdermal & Transmucosal Delivery of Therapeutics, 2nd Edition
U.S. Transdermal Drug Delivery Markets
Drug Delivery for Self-Administration Report - Technologies, Combination
Injectable Drug Delivery
Drug Delivery in Cancer - Technologies, Markets and Companies
Drug Delivery Technology - Revolutionizing CNS Therapies
|
|
|
|
